1435 related articles for article (PubMed ID: 28353286)
21. The emerging role of LRRK2 in tauopathies.
Herbst S; Lewis PA; Morris HR
Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
[TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
23. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
eNeuro; 2019; 6(6):. PubMed ID: 31685675
[TBL] [Abstract][Full Text] [Related]
25. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
26. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
27. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
[TBL] [Abstract][Full Text] [Related]
28. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
Konno T; Siuda J; Wszolek ZK
Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
[TBL] [Abstract][Full Text] [Related]
29. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
Chen ML; Wu RM
J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
31. LRRK2 and Proteostasis in Parkinson's Disease.
Pérez-Carrión MD; Posadas I; Solera J; Ceña V
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743250
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
33. Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.
Skibinski G; Hwang V; Ando DM; Daub A; Lee AK; Ravisankar A; Modan S; Finucane MM; Shaby BA; Finkbeiner S
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1165-1170. PubMed ID: 28028237
[TBL] [Abstract][Full Text] [Related]
34. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
35. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
[TBL] [Abstract][Full Text] [Related]
36. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
37. LRRK2 activation in idiopathic Parkinson's disease.
Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
[TBL] [Abstract][Full Text] [Related]
38. The Role of LRRK2 in Neurodegeneration of Parkinson Disease.
Rui Q; Ni H; Li D; Gao R; Chen G
Curr Neuropharmacol; 2018; 16(9):1348-1357. PubMed ID: 29473513
[TBL] [Abstract][Full Text] [Related]
39. The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.
Manzoni C
Biochem Soc Trans; 2017 Feb; 45(1):155-162. PubMed ID: 28202669
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
